腎線維症:治療薬開発パイプライン分析

Global Markets Directが発行した調査報告書(GMDHC9798IDB)
◆英語タイトル:Kidney Fibrosis - Pipeline Review, H2 2017
◆商品コード:GMDHC9798IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年10月17日
◆ページ数:133
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における腎線維症の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・腎線維症の概要
・腎線維症治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・腎線維症パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・腎線維症治療薬開発に取り組んでいる企業:企業別製品パイプライン
・腎線維症治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Kidney Fibrosis – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis – Pipeline Review, H2 2017, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 29 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 6
Global Markets Direct Report Coverage 6
Kidney Fibrosis – Overview 7
Kidney Fibrosis – Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 15
Kidney Fibrosis – Therapeutics Assessment 16
Assessment by Target 16
Assessment by Mechanism of Action 19
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Kidney Fibrosis – Companies Involved in Therapeutics Development 27
AbbVie Inc 27
AdAlta Ltd 28
Angion Biomedica Corp 28
Apollo Endosurgery Inc 29
BiOrion Technologies BV 29
BLR Bio LLC 30
Cellmid Ltd 30
Epigen Biosciences Inc 31
Evotec AG 31
Galectin Therapeutics Inc 32
GenKyoTex SA 32
Genzyme Corp 33
Intercept Pharmaceuticals Inc 33
Isarna Therapeutics GmbH 34
MorphoSys AG 34
Pharmaxis Ltd 35
ProMetic Life Sciences Inc 35
Redx Pharma Plc 36
Regulus Therapeutics Inc 36
Sirnaomics Inc 37
Vascular Biogenics Ltd 37
Kidney Fibrosis – Drug Profiles 38
1D-11 – Drug Profile 38
AD-114 – Drug Profile 39
ANG-3070 – Drug Profile 42
ANG-3586 – Drug Profile 43
ANG-4021 – Drug Profile 44
BLR-400 – Drug Profile 45
BMP-7 – Drug Profile 46
BOT-191 – Drug Profile 48
CAB-102 – Drug Profile 49
CT-140 – Drug Profile 51
Drugs for Tissue Fibrosis – Drug Profile 52
GAL-300 – Drug Profile 53
Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis – Drug Profile 54
GKT-136901 – Drug Profile 55
GRMD-02 – Drug Profile 57
ICG-001 – Drug Profile 71
INT-767 – Drug Profile 72
IP-9 – Drug Profile 73
ISTH-0047 – Drug Profile 74
LJ-1888 – Drug Profile 76
Lpathomab – Drug Profile 77
melittin – Drug Profile 80
MOR-107 – Drug Profile 81
MSB-003 – Drug Profile 82
MSB-014 – Drug Profile 83
P-007 – Drug Profile 84
PAT-1251 – Drug Profile 85
PAT-505 – Drug Profile 86
PBI-4050 – Drug Profile 87
PXS-4820 – Drug Profile 95
PXS-5033A – Drug Profile 96
PXS-5382A – Drug Profile 97
REDX-06109 – Drug Profile 98
RG-012 – Drug Profile 99
Small Molecule to Antagonize AlphaV and Beta6 for Fibrosis – Drug Profile 103
Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis – Drug Profile 104
Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis – Drug Profile 105
SOL-1 – Drug Profile 106
STP-705 – Drug Profile 107
Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis – Drug Profile 110
TEW-7197 – Drug Profile 111
VB-0004 – Drug Profile 113
VB-201 – Drug Profile 114
VB-703 – Drug Profile 117
Wnt-001 – Drug Profile 118
Kidney Fibrosis – Dormant Projects 119
Kidney Fibrosis – Product Development Milestones 120
Featured News & Press Releases 120
Appendix 129
Methodology 129
Coverage 129
Secondary Research 129
Primary Research 129
Expert Panel Validation 129
Contact Us 129
Disclaimer 130

List of Tables
Number of Products under Development for Kidney Fibrosis, H2 2017 11
Number of Products under Development by Companies, H2 2017 13
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
Number of Products under Development by Universities/Institutes, H2 2017 15
Products under Development by Companies, H2 2017 16
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17
Products under Development by Universities/Institutes, H2 2017 18
Number of Products by Stage and Target, H2 2017 20
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 21
Number of Products by Stage and Mechanism of Action, H2 2017 23
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 24
Number of Products by Stage and Route of Administration, H2 2017 26
Number of Products by Stage and Molecule Type, H2 2017 28
Kidney Fibrosis - Pipeline by AbbVie Inc, H2 2017 29
Kidney Fibrosis - Pipeline by AdAlta Ltd, H2 2017 30
Kidney Fibrosis - Pipeline by Angion Biomedica Corp, H2 2017 30
Kidney Fibrosis - Pipeline by Apollo Endosurgery Inc, H2 2017 31
Kidney Fibrosis - Pipeline by BiOrion Technologies BV, H2 2017 31
Kidney Fibrosis - Pipeline by BLR Bio LLC, H2 2017 32
Kidney Fibrosis - Pipeline by Cellmid Ltd, H2 2017 32
Kidney Fibrosis - Pipeline by Epigen Biosciences Inc, H2 2017 33
Kidney Fibrosis - Pipeline by Evotec AG, H2 2017 33
Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc, H2 2017 34
Kidney Fibrosis - Pipeline by GenKyoTex SA, H2 2017 34
Kidney Fibrosis - Pipeline by Genzyme Corp, H2 2017 35
Kidney Fibrosis - Pipeline by Intercept Pharmaceuticals Inc, H2 2017 35
Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2017 36
Kidney Fibrosis - Pipeline by MorphoSys AG, H2 2017 36
Kidney Fibrosis - Pipeline by Pharmaxis Ltd, H2 2017 37
Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc, H2 2017 37
Kidney Fibrosis - Pipeline by Redx Pharma Plc, H2 2017 38
Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc, H2 2017 38
Kidney Fibrosis - Pipeline by Sirnaomics Inc, H2 2017 39
Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd, H2 2017 39
Kidney Fibrosis - Dormant Projects, H2 2017 121

List of Figures
Number of Products under Development for Kidney Fibrosis, H2 2017 11
Number of Products under Development by Companies, H2 2017 12
Number of Products by Top 10 Targets, H2 2017 19
Number of Products by Stage and Top 10 Targets, H2 2017 19
Number of Products by Top 10 Mechanism of Actions, H2 2017 22
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 22
Number of Products by Routes of Administration, H2 2017 25
Number of Products by Stage and Routes of Administration, H2 2017 25
Number of Products by Molecule Types, H2 2017 27
Number of Products by Stage and Molecule Types, H2 2017 27

【レポートのキーワード】

腎線維症

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 腎線維症:治療薬開発パイプライン分析(Kidney Fibrosis - Pipeline Review, H2 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆